Discordant Responses to Potent Antiretroviral Treatment in Previously Naive HIV-1-Infected Adults Initiating Treatment in Resource-Constrained Countries
- 1 May 2007
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 45 (1) , 52-59
- https://doi.org/10.1097/qai.0b013e318042e1c3
Abstract
To assess the frequency of and risk factors for discordant responses at 6 months on highly active antiretroviral therapy (HAART) in previously treatment-naive HIV patients from resource-limited countries. The Antiretroviral Therapy in Low-Income Countries Collaboration is a network of clinics providing care and treatment to HIV-infected patients in Africa, Latin America, and Asia. Patients who initiated therapy between 1996 and 2004, were aged 16 years or older, and had a baseline CD4 cell count were included in this analysis. Responses were defined based on plasma viral load (PVL) and CD4 cell count at 6 months as complete virologic and immunologic (VR(+)IR(+)), virologic only (VR(+)IR(-)), immunologic only (VR(-)IR(+)), and nonresponse (VR(-)IR(-)). Multinomial logistic regression was used to assess the association between therapy responses and clinical and demographic variables. Of the 3111 patients eligible for analysis, 1914 had available information at 6 months of therapy: 1074 (56.1%) were VR(+)IR(+), 364 (19.0%) were VR(+)IR(-), 283 (14.8%) were (VR(-)IR(+)), and 193 (10.1%) were VR(-)IR(-). OF THE 3111 patients eligible for analysis, 1914 had available information at 6 months of therapy: 1074 (56.1%) were VRIR, 364 (19.0%) were VRIR, 283 (14.8%) were (VRIR), and 193 (10.1%) were VRIR. Compared with complete responders, virologic-only responders were older, had a higher baseline CD4 cell count, had a lower baseline PVL, and were more likely to have received a nonstandard HAART regimen; immunologic-only responders were younger, had a lower baseline CD4 cell count, had a higher baseline PVL, and were more likely to have received a protease inhibitor-based regimen. The frequency of and risk factors for discordant responses were comparable to those observed in developed countries. Longer follow-up is needed to assess the long-term impact of discordant responses on mortality in these resource-limited settings.Keywords
This publication has 41 references indexed in Scilit:
- Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohortsInternational Journal of Epidemiology, 2005
- Clinical outcome after 4 years follow‐up of HIV‐seropositive subjects with incomplete virologic or immunologic response to HAARTJournal of Medical Virology, 2005
- Medication adherence in HIV-infected adultsAIDS, 2004
- Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studiesAIDS, 2003
- Can Immune Markers Predict Subsequent Discordance between Immunologic and Virologic Responses to Antiretroviral Therapy? Adult AIDS Clinical Trials GroupClinical Infectious Diseases, 2003
- Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in SenegalAIDS, 2003
- Prolonged CD4+Cell/Virus Load Discordance during Treatment with Protease Inhibitor–Based Highly Active Antiretroviral Therapy: Immune Response and Viral ControlThe Journal of Infectious Diseases, 2003
- Review of Human Immunodeficiency Virus Type 1–Related Opportunistic Infections in Sub‐Saharan AfricaClinical Infectious Diseases, 2003
- Differences in Cellular Activation and Apoptosis in HIV-Infected Patients Receiving Protease Inhibitors or Nonnucleoside Reverse Transcriptase InhibitorsAIDS Research and Human Retroviruses, 2002
- Prognostic Factors of Combined Viral Load and CD4+ Cell Count Responses Under Triple Antiretroviral Therapy, Aquitaine Cohort, 1996–1998JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001